Lamisil (Terbinafine Hydrochloride)

Terbinafine blocks the fungal enzyme squalene epoxidase, which is essential for producing ergosterol, a key component of the fungal cell membrane. Inhibition leads to a buildup of toxic squalene and a shortage of ergosterol, disrupting membrane integrity and ultimately causing fungal cell death.

The specific amount of Lamisil to apply, the frequency of application, and the total duration of therapy are determined by a qualified healthcare professional based on the infection type, severity, patient age and other clinical factors. Patients should follow the prescriber’s instructions precisely.

Safety data for topical terbinafine during pregnancy and lactation are limited. Healthcare providers usually weigh the potential benefits against any possible risks before prescribing. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss the use of Lamisil with their physician.

To request Lamisil, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After the enquiry, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details and any necessary import documentation.

Compared with azole antifungals, terbinafine has a different mechanism of action, targeting squalene epoxidase rather than lanosterol 14‑α‑demethylase. This can result in faster clinical cure rates for dermatophyte infections and a lower likelihood of drug‑drug interactions mediated by CYP enzymes. Choice of therapy depends on infection type, patient factors and local resistance patterns.

Lamisil should be stored at room temperature below 25 °C, in its original container, protected from moisture, heat and direct sunlight. Keep the product out of reach of children and avoid freezing. If the cream appears discoloured or contaminated, discard it according to local regulations.

Clean and gently dry the affected skin area before applying a thin layer of Lamisil. Use enough cream to cover the lesion and a small margin of surrounding skin. Apply once or twice daily as directed by the prescriber, and continue treatment for the full course even if symptoms improve early.

Although rare, serious adverse events can include severe allergic reactions such as swelling, hives, or difficulty breathing, and contact dermatitis with intense inflammation or blistering. Systemic absorption may rarely cause liver enzyme elevations. Patients should stop use and seek medical attention if any of these symptoms develop.

Lamisil should be avoided in individuals with known hypersensitivity to terbinafine, other allylamine antifungals, or any component of the formulation. It is also contraindicated on extensive broken skin or open wounds, and caution is advised for pregnant or breastfeeding women until safety is confirmed by a healthcare professional.